Protalix Biotherapeutics Stock Price, News & Analysis (NYSEAMERICAN:PLX)

$0.62 0.00 (0.00 %)
(As of 12/14/2017 01:04 AM ET)
Previous Close$0.62
Today's Range$0.62 - $0.64
52-Week Range$0.28 - $1.51
Volume474,300 shs
Average Volume1.83 million shs
Market Capitalization$304.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98

About Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:PLX
CUSIPN/A
Phone+972-4-9028100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares139,730,000

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its earnings results on Wednesday, November, 8th. The company reported ($0.09) EPS for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.04. The business had revenue of $7.53 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the prior year, the company posted ($0.07) earnings per share. View Protalix Biotherapeutics' Earnings History.

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 Wall Street analysts have issued 12-month price targets for Protalix Biotherapeutics' stock. Their forecasts range from $1.00 to $5.00. On average, they expect Protalix Biotherapeutics' share price to reach $3.67 in the next year. View Analyst Ratings for Protalix Biotherapeutics.

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 6,457,835 shares, a drop of 12.2% from the November 15th total of 7,354,475 shares. Based on an average daily volume of 1,127,531 shares, the days-to-cover ratio is currently 5.7 days. Currently, 5.0% of the company's shares are sold short.

Who are some of Protalix Biotherapeutics' key competitors?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the folowing people:

  • Shlomo Yanai, Chairman of the Board (Age 64)
  • Moshe Manor, President, Chief Executive Officer, Director (Age 60)
  • Yossi Maimon CPA, Chief Financial Officer, Vice President, Treasurer, Secretary (Age 46)
  • Tzvi Palash, Chief Operating Officer (Age 60)
  • Yoseph Shaaltiel Ph.D., Executive Vice President - Research & Development (Age 63)
  • Einat Brill Almon Ph.D., Senior Vice President - Product Development (Age 57)
  • Amos Bar-Shalev, Independent Director (Age 64)
  • Zeev Bronfeld, Independent Director (Age 66)
  • Yodfat Harel Buchris, Independent Director (Age 45)
  • Roger D. Kornberg Ph.D., Independent Director (Age 69)

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.62.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $304.55 million.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.


MarketBeat Community Rating for Protalix Biotherapeutics (PLX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.95$2.95$2.95$2.27
Price Target Upside: 321.43% upside333.82% upside375.81% upside190.60% upside

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Consensus Price Target History

Price Target History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/29/2017HC WainwrightSet Price TargetBuy$5.00View Rating Details
5/23/2017Rodman & RenshawReiterated RatingBuy$5.00View Rating Details
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies GroupLower Price TargetBuy$1.75 -> $0.80View Rating Details
(Data available from 12/14/2015 forward)

Earnings

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Earnings History and Estimates Chart

Earnings by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix Biotherapeutics (NYSEAMERICAN PLX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.05)($0.09)$6.65 million$7.53 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.04)($0.06)$5.05 million$6.36 millionViewListenView Earnings Details
5/10/2017Q1 17($0.09)($0.07)$2.55 million$2.89 millionViewN/AView Earnings Details
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/9/2015Q3 15($0.08)($0.04)$5.00 million$4.30 millionViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.05)$6.40 million$3.78 millionViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)$8.20 million$4.39 millionViewN/AView Earnings Details
8/7/2014($0.07)($0.07)$9.63 million$2.43 millionViewN/AView Earnings Details
5/8/2014($0.07)($0.08)$8.25 million$6.70 millionViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)$5.54 million$2.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Protalix Biotherapeutics (NYSEAMERICAN PLX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix Biotherapeutics (NYSEAMERICAN PLX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Steve DabnerDirectorBuy6,000$0.32$1,920.00
8/31/2017Steve DabnerDirectorBuy10,000$0.33$3,300.00
7/28/2017Steve DabnerDirectorBuy500$0.36$180.00
7/26/2017Steve DabnerDirectorBuy3,500$0.35$1,225.00
7/25/2017Steve DabnerDirectorBuy10,000$0.35$3,500.00
6/2/2017Randall Peel BoydInsiderBuy38,300$0.47$18,001.00
5/16/2017Moshe ManorCEOBuy50,000$0.81$40,500.00View SEC Filing  
1/27/2017Terence Stanley MeekDirectorBuy12,000$0.42$5,040.00
1/25/2017Madalena Energy Inc.InsiderSell190,500$0.38$72,390.00
1/23/2017Madalena Energy Inc.InsiderSell500$0.39$195.00
1/12/2017Madalena Energy Inc.InsiderSell54,000$0.42$22,680.00
1/11/2017Madalena Energy Inc.InsiderSell51,000$0.44$22,440.00
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Protalix Biotherapeutics (NYSEAMERICAN PLX) News Headlines

Source:
DateHeadline
Protalix Biotherapeutics Inc (PLX) Short Interest UpdateProtalix Biotherapeutics Inc (PLX) Short Interest Update
www.americanbankingnews.com - December 12 at 1:50 AM
Protalix Biotherapeutics (PLX) Cut to Strong Sell at BidaskClubProtalix Biotherapeutics (PLX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - December 2 at 4:04 PM
Protalix BioTherapeutics (PLX) Completes Enrollment in Phase II ... - StreetInsider.comProtalix BioTherapeutics (PLX) Completes Enrollment in Phase II ... - StreetInsider.com
www.streetinsider.com - November 30 at 10:46 AM
Protalix BioTherapeutics (PLX) Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with UCProtalix BioTherapeutics (PLX) Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with UC
www.streetinsider.com - November 29 at 4:52 PM
Protalix Biotherapeutics (PLX) PT Set at $5.00 by HC WainwrightProtalix Biotherapeutics (PLX) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - November 29 at 12:22 PM
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis - GlobeNewswire (press release)Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis - GlobeNewswire (press release)
globenewswire.com - November 29 at 10:16 AM
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative ColitisProtalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
finance.yahoo.com - November 29 at 10:15 AM
Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:15 AM
Protalix Reports Positive Results From Phase1/II Trial Of PRX-102Protalix Reports Positive Results From Phase1/II Trial Of PRX-102
www.rttnews.com - November 27 at 4:33 PM
Protalix Reports Positive Results From Phase1/II Trial Of PRX-102 - NasdaqProtalix Reports Positive Results From Phase1/II Trial Of PRX-102 - Nasdaq
www.nasdaq.com - November 27 at 3:44 PM
Protalix BioTherapeutics (PLX) Presents Positive Results from Phase I/II Open-Label Extension Trial for PRX-102 at ... - StreetInsider.comProtalix BioTherapeutics (PLX) Presents Positive Results from Phase I/II Open-Label Extension Trial for PRX-102 at ... - StreetInsider.com
www.streetinsider.com - November 27 at 8:02 AM
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease ConferenceProtalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
finance.yahoo.com - November 27 at 8:02 AM
Protalix BioTherapeutics: An Update On The Fabry Disease Franchise - Seeking AlphaProtalix BioTherapeutics: An Update On The Fabry Disease Franchise - Seeking Alpha
seekingalpha.com - November 23 at 5:42 PM
Global Biotechnology Market Showing Potential for Further GrowthGlobal Biotechnology Market Showing Potential for Further Growth
www.prnewswire.com - November 21 at 9:23 AM
Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EUCorporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU
finance.yahoo.com - November 15 at 7:31 AM

SEC Filings

Protalix Biotherapeutics (NYSEAMERICAN:PLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Protalix Biotherapeutics (NYSEAMERICAN PLX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.